NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 05, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total revenues	$ 500,919	$ 750,530	$ 1,655,077	$ 1,388,574
Roche Collaboration and License Agreement | Roche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transactional price remaining performance obligation	922,000		922,000
Total revenues	14,884	310,200	99,832	310,200
Global Strategic Collaboration | Regeneron Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transactional price remaining performance obligation	166,687		166,687		$ 329,686
Fixed Consideration					270,300
Variable Consideration Allocated					59,386
Total revenues	19,500	73,700	48,700	72,700
Roche License Obligation | Roche Collaboration and License Agreement | Roche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transactional price remaining performance obligation	375,000		375,000
Total revenues	0	310,000	65,000	310,000
Roche Development Services Obligation | Roche Collaboration and License Agreement | Roche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transactional price remaining performance obligation	545,000		545,000
Total revenues	14,884	200	34,832	200
Roche Technology Transfer Obligation | Roche Collaboration and License Agreement | Roche
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transactional price remaining performance obligation	2,000		2,000
Total revenues	0	0	0	0
Research Services Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transactional price remaining performance obligation	100,583		100,583		75,469
Standalone Selling Price					78,820
Fixed Consideration					45,469
Variable Consideration Allocated					30,000
Total revenues	11,100	73,000	29,800	66,700
C5 License Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transactional price remaining performance obligation	60,191		60,191		56,390
Standalone Selling Price					53,745
Fixed Consideration					31,004
Variable Consideration Allocated					25,386
Total revenues	8,400	$ 700	18,900	$ 6,000
C5 Monotherapy Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transactional price remaining performance obligation					191,520
Standalone Selling Price					332,000
Fixed Consideration					191,520
Variable Consideration Allocated					0
Regeneron Technology Transfer Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transactional price remaining performance obligation	$ 5,913		$ 5,913		6,307
Standalone Selling Price					4,000
Fixed Consideration					2,307
Variable Consideration Allocated					$ 4,000